Elarex, Inc.
Elarex Inc. specializes in stabilizing biologicals, especially vaccines, through breakthrough technology that enhances temperature stability and simplifies distribution. Their mission is to improve global health by enabling vaccines and biologics to be stored and transported outside the cold chain, making them more accessible and reducing waste. Their vision is to create a healthier, more equitable world by providing innovative solutions to vaccine distribution challenges.
Industries
Nr. of Employees
small (1-50)
Products
Patented dried stabilization formulation (sugar/glass matrix)
A patented dried formulation composed of pullulan- and sugar-based components designed to stabilize vaccines, viral vectors, and other biologics for extended storage at elevated temperatures; developed as a platform to be adapted to multiple payloads.
Patented dried stabilization formulation (sugar/glass matrix)
A patented dried formulation composed of pullulan- and sugar-based components designed to stabilize vaccines, viral vectors, and other biologics for extended storage at elevated temperatures; developed as a platform to be adapted to multiple payloads.
Services
Development and adaptation of dried sugar-based formulations for improved temperature stability of vaccines and other biologics.
Design and execution of accelerated and real-time stability studies plus in vivo preclinical testing to assess potency and immunogenicity after storage.
Development of lab-scale workflows for producing dried/dissolvable vaccine prototypes intended for integration into existing production lines without freeze-drying.
Development and adaptation of dried sugar-based formulations for improved temperature stability of vaccines and other biologics.
Design and execution of accelerated and real-time stability studies plus in vivo preclinical testing to assess potency and immunogenicity after storage.
Development of lab-scale workflows for producing dried/dissolvable vaccine prototypes intended for integration into existing production lines without freeze-drying.
Expertise Areas
- Vaccine formulation and stabilization
- Thermostability testing and validation
- Preclinical vaccine evaluation (animal immunogenicity)
- Formulation process and drying engineering
Key Technologies
- Pullulan-based sugar films
- Trehalose and disaccharide stabilization
- Sugar-glass / solid-state formulations
- Enhanced vacuum drying
News & Updates
Elarex Inc. was selected to participate in the Canadian Technology Accelerator in Boston, a program run by the Canadian consulate, to help accelerate their impact in the biotech marketplace and refine their company strategy.
Elarex Inc., a company spun out from McMaster University, received a $1.2M Canadian grant from the Bill & Melinda Gates Foundation to develop a technology for keeping liquid mRNA vaccines viable without deep-freeze storage, facilitating better global distribution.
Elarex Inc. was selected to participate in the Canadian Technology Accelerator in Boston, a program run by the Canadian consulate, to help accelerate their impact in the biotech marketplace and refine their company strategy.
Elarex Inc., a company spun out from McMaster University, received a $1.2M Canadian grant from the Bill & Melinda Gates Foundation to develop a technology for keeping liquid mRNA vaccines viable without deep-freeze storage, facilitating better global distribution.